{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:56:36Z","timestamp":1790200596108,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009098","name":"Japanese Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.resinv.2023.08.007","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T23:25:16Z","timestamp":1695252316000},"page":"773-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Management goals and stable phase management of patients with chronic obstructive pulmonary disease in the Japanese respiratory society guideline for the management of chronic obstructive pulmonary disease 2022 (6th edition)"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1794-0026","authenticated-orcid":false,"given":"Yoko","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Kawayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatoshi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2023.08.007_bib1","series-title":"Overview of COPD the JRS guideline for the management of chronic obstructive pulmonary disease 2022","first-page":"8","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1440-1843.2004.00637.x","article-title":"COPD in Japan: the nippon COPD epidemiology study","volume":"9","author":"Fukuchi","year":"2004","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2023.08.007_bib3","series-title":"Epidemiology and socio-economic burden of COPD. The JRS guideline for the management of chronic obstructive pulmonary disease 2022","first-page":"13","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib4","series-title":"Japanese respiratory society","first-page":"149","article-title":"Management of exacerbation phase","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/thoraxjnl-2014-205507","article-title":"The path to personalised medicine in COPD","volume":"69","author":"Agusti","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2023.08.007_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1465-9921-11-122","article-title":"Characterisation of COPD heterogeneity in the ECLIPSE cohort","volume":"11","author":"Agusti","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2023.08.007_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2213-2600(19)30276-0","article-title":"Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study","volume":"8","author":"Oelsner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2023.08.007_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2023.08.007_bib10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Catalu\u00f1a","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2023.08.007_bib11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1164\/rccm.202005-1854OC","article-title":"Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease. A systematic review","volume":"203","author":"Celli","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.08.007_bib12","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.08.007_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.08.007_bib14","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1007\/s12325-020-01411-0","article-title":"Efficacy of tiotropium\/olodaterol compared with tiotropium as a first-line maintenance treatment in patients with COPD who are na\u00efve to LAMA, LABA and ICS: pooled analysis of four clinical trials","volume":"37","author":"Buhl","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2023.08.007_bib15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1183\/09031936.00124013","article-title":"Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study","volume":"43","author":"Mahler","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2023.08.007_bib16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.chest.2017.07.007","article-title":"Baseline symptom score impact on benefits of glycopyrrolate\/formoterol metered dose inhaler in COPD","volume":"152","author":"Martinez","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2023.08.007_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/resp.13651","article-title":"Indacaterol\/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-na\u00efve COPD patients: a pooled analysis","volume":"25","author":"Muro","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2023.08.007_bib18","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2147\/COPD.S268905","article-title":"First-line treatment with tiotropium\/olodaterol improves physical activity in patients with treatment-na\u00efve chronic obstructive pulmonary disease","volume":"15","author":"Takahashi","year":"2020","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2023.08.007_bib19","series-title":"The JRS guideline for the management of chronic obstructive pulmonary disease 2022","first-page":"212","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib20","series-title":"The JRS Guidelines for the management of ACO 2018","first-page":"94","year":"2018"},{"key":"10.1016\/j.resinv.2023.08.007_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01586-2018","article-title":"Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis","volume":"52","author":"Cazzola","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2023.08.007_bib22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2023.08.007_bib23","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.2147\/COPD.S220861","article-title":"Long-term safety and efficacy of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using Co-suspension delivery technology in Japanese patients with COPD","volume":"14","author":"Ichinose","year":"2019","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2023.08.007_bib24","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.2147\/COPD.S226601","article-title":"The impact study - single inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI and UMEC\/VI in patients with COPD: efficacy and safety in A Japanese population","volume":"14","author":"Kato","year":"2019","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2023.08.007_bib25","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2023.08.007_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2023.08.007_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12931-021-01777-x","article-title":"Triple versus LAMA\/LABA combination therapy for patients with COPD: a systematic review and meta-analysis","volume":"22","author":"Koarai","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2023.08.007_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.resinv.2021.04.007","article-title":"Triple versus LAMA\/LABA combination therapy for Japanese patients with COPD: a systematic review and meta-analysis","volume":"60","author":"Koarai","year":"2022","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2023.08.007_bib29","doi-asserted-by":"crossref","first-page":"k4388","DOI":"10.1136\/bmj.k4388","article-title":"Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis","volume":"363","author":"Zheng","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.resinv.2023.08.007_bib30","series-title":"Diagnostic guidelines and criteria. The JRS Guidelines for the management of ACO 2018","first-page":"44","year":"2018"},{"key":"10.1016\/j.resinv.2023.08.007_bib31","first-page":"Cd012066","article-title":"Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)","volume":"2","author":"Horita","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.resinv.2023.08.007_bib32","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1164\/rccm.2105106","article-title":"Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease","volume":"165","author":"Culpitt","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.08.007_bib33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1183\/09031936.00208011","article-title":"Macrolide effects on the prevention of COPD exacerbations","volume":"40","author":"Yamaya","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2023.08.007_bib34","series-title":"The JRS guideline for the management of chronic obstructive pulmonary disease 2022","first-page":"222","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib35","series-title":"The JRS guideline for the management of chronic obstructive pulmonary disease 2022","first-page":"236","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib36","series-title":"The JRS guideline for the management of chronic obstructive pulmonary disease 2022","first-page":"242","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib37","series-title":"The JRS guideline for the management of chronic obstructive pulmonary disease 2022","first-page":"248","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib38","series-title":"The JRS guideline for the management of chronic obstructive pulmonary disease 2022","first-page":"253","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib39","series-title":"Management of stable phase","first-page":"96","year":"2022"},{"key":"10.1016\/j.resinv.2023.08.007_bib40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.resinv.2020.05.010","article-title":"Effect of pulmonary rehabilitation programs including lower limb endurance training on dyspnea in stable COPD: a systematic review and meta-analysis","volume":"58","author":"Higashimoto","year":"2020","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2023.08.007_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09736","article-title":"A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils","volume":"8","author":"Ohnishi","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.resinv.2023.08.007_bib42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.resinv.2021.08.002","article-title":"Treatment efficacy of LAMA versus placebo for stable chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"60","author":"Suzuki","year":"2022","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2023.08.007_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/14799731231166008","article-title":"The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"20","author":"Tanimura","year":"2023","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.resinv.2023.08.007_bib45","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1007\/s12325-022-02167-5","article-title":"Real-world status of medical care and treatment of chronic obstructive pulmonary disease by respiratory specialists in Japan","volume":"39","author":"Hashimoto","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2023.08.007_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/COPD.S385186","article-title":"Real-world evidence on the diagnostic and clinical characteristics of asthma in Japanese patients with COPD: the ACO Japan cohort study","volume":"18","author":"Hashimoto","year":"2023","journal-title":"Int J Chronic Obstr Pulm Dis"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534523000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534523000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:33:36Z","timestamp":1761950016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534523000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2212534523000849"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2023.08.007","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management goals and stable phase management of patients with chronic obstructive pulmonary disease in the Japanese respiratory society guideline for the management of chronic obstructive pulmonary disease 2022 (6th edition)","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2023.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}